论文部分内容阅读
目的:评价替考拉宁治疗下呼吸道革兰阳性菌感染的疗效和安全性。方法:给药方案为试验药替考拉宁,第一日每次400mg,qd,此后每次200mg,qd;重度感染第一日每次400mg,q12h,此后每次400mg,qd。对照药万古霉素,每次0、5g,q8h。重度感染每次1.0g,q12h。均为静脉滴注。疗程7～14d。结果:试验药组和对照药组有效率分别为87.10％（54/62）及90.32％（56/62）,痊愈率分别为74.19％（46/62）及61.29％（38/62）,细菌清除率分别为94.74％（54/57）及88.52％（54/61）,药物不良反应发生率分别为11.29％（7/62）及6.45％（4/62）。上述两组的各项结果经统计学处理,均无显著性差异（P>0.05）。结论:替考拉宁对革兰阳性菌抗菌活性强,临床疗效佳,药物不良反应轻微,对革兰阳性菌引起的中、重度感染安全有效。
Objective: To evaluate the efficacy and safety of teicoplanin in the treatment of Gram-positive bacterial infections of lower respiratory tract. Methods: The dosing regimen was test drug teicoplanin, the first day of each 400mg, qd, then every 200mg, qd; severe infection on the first day of each 400mg, q12h, since each 400mg, qd. Control drug vancomycin, each 0,5 g, q8h. Severe infections each 1.0g, q12h. All intravenous drip. Treatment 7 ~ 14d. Results: The effective rates of the experimental group and the control group were 87.10% (54/62) and 90.32% (56/62), respectively. The cure rates were 74.19% (46/62) and 61.29% (38/62) respectively. The clearance rates were 94.74% (54/57) and 88.52% (54/61), respectively. The adverse drug reactions were 11.29% (7/62) and 6.45% (4/62) respectively. The results of the above two groups by statistical analysis, no significant difference (P> 0.05). Conclusion: Teicoplanin has strong antibacterial activity against Gram-positive bacteria, good clinical curative effect and mild adverse drug reaction. It is safe and effective for moderate and severe infections caused by Gram-positive bacteria.